Literature DB >> 26610167

A Randomized Controlled Clinical Trial of Dialogical Exposure Therapy versus Cognitive Processing Therapy for Adult Outpatients Suffering from PTSD after Type I Trauma in Adulthood.

Willi Butollo1, Regina Karl, Julia König, Rita Rosner.   

Abstract

BACKGROUND: Although there are effective treatments for posttraumatic stress disorder (PTSD), there is little research on treatments with non-cognitive-behavioural backgrounds, such as gestalt therapy. We tested an integrative gestalt-derived intervention, dialogical exposure therapy (DET), against an established cognitive-behavioural treatment (cognitive processing therapy, CPT) for possible differential effects in terms of symptomatic outcome and drop-out rates.
METHODS: We randomized 141 treatment-seeking individuals with a diagnosis of PTSD to receive either DET or CPT. Therapy length in both treatments was flexible with a maximum duration of 24 sessions.
RESULTS: Dropout rates were 12.2% in DET and 14.9% in CPT. Patients in both conditions achieved significant and large reductions in PTSD symptoms (Impact of Event Scale - Revised; Hedges' g = 1.14 for DET and d = 1.57 for CPT) which were largely stable at the 6-month follow-up. At the posttreatment assessment, CPT performed statistically better than DET on symptom and cognition measures. For several outcome measures, younger patients profited better from CPT than older ones, while there was no age effect for DET.
CONCLUSIONS: Our results indicate that DET merits further research and may be an alternative to established treatments for PTSD. It remains to be seen whether DET confers advantages in areas of functioning beyond PTSD symptoms.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26610167     DOI: 10.1159/000440726

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  7 in total

Review 1.  Lost in Transition? Evidence-Based Treatments for Adolescents and Young Adults with Posttraumatic Stress Disorder and Results of an Uncontrolled Feasibility Trial Evaluating Cognitive Processing Therapy.

Authors:  Anna Vogel; Rita Rosner
Journal:  Clin Child Fam Psychol Rev       Date:  2020-03

2.  Protocol for individual participant data meta-analysis of interventions for post-traumatic stress.

Authors:  Simonne Lesley Wright; Eirini Karyotaki; Jonathan I Bisson; Pim Cuijpers; Davide Papola; Anke B Witteveen; Soraya Seedat; Marit Sijbrandij
Journal:  BMJ Open       Date:  2022-02-15       Impact factor: 2.692

Review 3.  Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis.

Authors:  Catrin Lewis; Neil P Roberts; Samuel Gibson; Jonathan I Bisson
Journal:  Eur J Psychotraumatol       Date:  2020-03-09

Review 4.  Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis.

Authors:  Catrin Lewis; Neil P Roberts; Martin Andrew; Elise Starling; Jonathan I Bisson
Journal:  Eur J Psychotraumatol       Date:  2020-03-10

5.  Exploring memory function in earthquake trauma survivors with resting-state fMRI and machine learning.

Authors:  Yuchen Li; Hongru Zhu; Zhengjia Ren; Su Lui; Minlan Yuan; Qiyong Gong; Cui Yuan; Meng Gao; Changjian Qiu; Wei Zhang
Journal:  BMC Psychiatry       Date:  2020-02-03       Impact factor: 3.630

Review 6.  A systematic review of factors associated with outcome of psychological treatments for post-traumatic stress disorder.

Authors:  Kali S Barawi; Catrin Lewis; Natalie Simon; Jonathan I Bisson
Journal:  Eur J Psychotraumatol       Date:  2020-07-01

7.  A Randomized Clinical Trial to Assess the Efficacy of Online-Treatment with Trial-Based Cognitive Therapy, Mindfulness-Based Health Promotion and Positive Psychotherapy for Post-Traumatic Stress Disorder during the COVID-19 Pandemic: A Study Protocol.

Authors:  Érica Panzani Duran; Curt Hemanny; Renata Vieira; Orlando Nascimento; Leonardo Machado; Irismar Reis de Oliveira; Marcelo Demarzo
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.